Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil Fleshner

Showing results (251-260 of 266) with videos related to

Pageof 27
Sort By:
European Urology Oncology|September 25, 2025
Prognostic Significance of the Cytoplasmic Expression of UDP-glucuronosyltransferase 2B17 in Localized Prostate Cancer: Insights from the Canadian Prostate Cancer Biomarker Network and PROCURE Multi-institutional CohortsAshwini Uchil, Louis Lacombe, Hélène Hovington, et al.
The Journal of Urology|January 10, 2004
First International Conference on Chemoprevention of Prostate Cancer. Overview consensus statementIan M Thompson, Demetrius Albanes, Joseph W Basler, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|March 16, 2016
Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015Wassim Kassouf, Armen Aprikian, Peter Black, et al.
Prostate Cancer and Prostatic Diseases|December 14, 2018
Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillanceHyung L Kim, Ping Li, Huei-Chung Huang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2017
Neoadjuvant Enzalutamide Prior to ProstatectomyBruce Montgomery, Maria S Tretiakova, Anthony M Joshua, et al.
Urologic Oncology|January 10, 2017
Quality indicators in the management of bladder cancer: A modified Delphi studySatya R Khare, Armen Aprikian, Peter Black, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|May 25, 2016
Enumerating pelvic recurrence following radical cystectomy for bladder cancer: A Canadian multi-institutional studyLibni J Eapen, Edward Jones, Wassim Kassouf, et al.
The Oncologist|February 23, 2024
Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMISNeal D Shore, Christian Gratzke, Susan Feyerabend, et al.
Scientific Reports|July 24, 2021
Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasiaMichael A Kiebish, Poornima Tekumalla, Shobha Ravipaty, et al.
JCO Precision Oncology|February 26, 2019
epiCaPture: A Urine DNA Methylation Test for Early Detection of Aggressive Prostate CancerEve O'Reilly, Alexandra V Tuzova, Anna L Walsh, et al.
Pageof 27

Showing results (251-260 of 266) with videos related to

Sort By:
Pageof 27
European Urology Oncology|September 25, 2025
Prognostic Significance of the Cytoplasmic Expression of UDP-glucuronosyltransferase 2B17 in Localized Prostate Cancer: Insights from the Canadian Prostate Cancer Biomarker Network and PROCURE Multi-institutional CohortsAshwini Uchil, Louis Lacombe, Hélène Hovington, et al.
The Journal of Urology|January 10, 2004
First International Conference on Chemoprevention of Prostate Cancer. Overview consensus statementIan M Thompson, Demetrius Albanes, Joseph W Basler, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|March 16, 2016
Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015Wassim Kassouf, Armen Aprikian, Peter Black, et al.
Prostate Cancer and Prostatic Diseases|December 14, 2018
Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillanceHyung L Kim, Ping Li, Huei-Chung Huang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2017
Neoadjuvant Enzalutamide Prior to ProstatectomyBruce Montgomery, Maria S Tretiakova, Anthony M Joshua, et al.
Urologic Oncology|January 10, 2017
Quality indicators in the management of bladder cancer: A modified Delphi studySatya R Khare, Armen Aprikian, Peter Black, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|May 25, 2016
Enumerating pelvic recurrence following radical cystectomy for bladder cancer: A Canadian multi-institutional studyLibni J Eapen, Edward Jones, Wassim Kassouf, et al.
The Oncologist|February 23, 2024
Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMISNeal D Shore, Christian Gratzke, Susan Feyerabend, et al.
Scientific Reports|July 24, 2021
Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasiaMichael A Kiebish, Poornima Tekumalla, Shobha Ravipaty, et al.
JCO Precision Oncology|February 26, 2019
epiCaPture: A Urine DNA Methylation Test for Early Detection of Aggressive Prostate CancerEve O'Reilly, Alexandra V Tuzova, Anna L Walsh, et al.
Pageof 27